

Discovery through Machine Learning and Preclinical Validation of Novel Anti-Diabetic Peptides

Rory Casey¹, Alessandro Adelfio¹, Martin Connolly¹, Audrey Wall^{1*}, Ian Holyer¹ and Nora Khaldi¹

¹ Nuritas Ltd, Joshua Dawson House, Dublin 2, D02 RY95, Ireland

* Correspondence: **Author:** Dr Audrey Wall, PhD ; **Email:** wall.audrey@nuritas.com; **Phone:** +353 1 430 1290




Figure S1: AI predicted peptides in a mouse model of type 2 diabetes. Bodyweight (g) of all mice were measured as indicated. Data are mean \pm SEM (n=8 per group; aged 12 weeks at baseline) and analysed by Tukeys's test to compare the differences of bodyweight within each treatment group over the course of treatment (*p<0.05 **p<0.01 ***p<0.001)




Figure S2. Property dispersion of AI predicted peptides relative to known endogenous human peptides.